Geron Corporation
$ 1.68
-0.59%
17 Apr - close price
- Market Cap 1,076,713,000 USD
- Current Price $ 1.68
- High / Low $ 1.74 / 1.66
- Stock P/E N/A
- Book Value 0.35
- EPS -0.13
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -0.33 %
- 52 Week High 2.01
- 52 Week Low 1.04
About
Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic neoplasms. The company is headquartered in Foster City, California.
Analyst Target Price
$3.40
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-25 | 2025-11-05 | 2025-08-06 | 2025-04-30 | 2025-02-26 | 2024-11-07 | 2024-08-08 | 2024-05-02 | 2024-02-28 | 2023-11-02 | 2023-08-03 | 2023-05-11 |
| Reported EPS | -0.0212 | -0.03 | -0.02 | -0.03 | -0.0356 | -0.04 | -0.1 | -0.09 | -0.09 | -0.08 | -0.09 | -0.07 |
| Estimated EPS | -0.028 | -0.03 | -0.03 | -0.0357 | -0.0464 | -0.08 | -0.1 | -0.1 | -0.1 | -0.1 | -0.08 | -0.1 |
| Surprise | 0.0068 | 0 | 0.01 | 0.0057 | 0.0108 | 0.04 | 0 | 0.01 | 0.01 | 0.02 | -0.01 | 0.03 |
| Surprise Percentage | 24.2857% | 0% | 33.3333% | 15.9664% | 23.2759% | 50% | 0% | 10% | 10% | 20% | -12.5% | 30% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.03 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: GERN
2026-04-17 10:09:23
Short interest in Geron Corporation (NASDAQ:GERN) surged by 21.3% in March, reaching 76.67 million shares, which represents about 12.9% of the float. This increase indicates a growing bearish sentiment, despite high institutional ownership and analyst ratings that are mostly "Hold" with a consensus target price of $2.17. The biopharmaceutical company recently missed its quarterly earnings estimates and has a market capitalization of $1.08 billion.
2026-04-15 04:10:37
Geron Corporation announced it granted Timothy Williams, its new Executive Vice President, Chief Legal Officer, and Corporate Secretary, a stock option to purchase 2,500,000 shares. The option was granted on April 13, 2026, with an exercise price of $1.73 per share, matching the closing price on the grant date. This inducement award vests over four years and was approved under Nasdaq Listing Rule 5635(c)(4).
2026-04-15 04:10:36
Geron Corporation granted a stock option to purchase 2,500,000 shares of its common stock to Timothy Williams, the new Executive Vice President, Chief Legal Officer, and Corporate Secretary. This equity award, granted on April 13, 2026, serves as an inducement for his employment. The option has an exercise price of $1.73 per share, a ten-year term, and vests over four years, subject to continued service.
2026-04-15 00:40:36
Geron has appointed Timothy Williams as Executive Vice President, Chief Legal Officer, and Corporate Secretary, with an equity award as an inducement. This hire adds crucial legal and compliance experience for a commercial-stage biopharmaceutical company like Geron. The stock options tie Williams' compensation to the company's long-term performance, aligning his incentives with shareholder outcomes as Geron expands its commercial activities.
2026-04-15 00:40:36
Geron's EVP and Chief Legal Officer, Timothy Williams, has filed an initial Form 3 insider report, establishing his reporting person status with the SEC. This filing indicates no current beneficial ownership or transactions, serving purely as a baseline regulatory disclosure. The report confirms his role and signifies his obligation to report future changes in his ownership of company securities.
2026-04-15 00:40:36
Geron Corp. (GERN) has granted 2.5 million stock options to its EVP and Chief Legal Officer, Timothy Williams, with an exercise price of $1.73 per share and an expiration date of April 12, 2036. The options will begin vesting on October 13, 2026, with the remaining shares vesting in equal installments over the subsequent 42 months, contingent on his continued employment. This award is compensation-related and not an open-market transaction.
